Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma
Crossref DOI link: https://doi.org/10.1007/s11060-016-2234-6
Published Online: 2016-08-09
Published Print: 2016-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
McCracken, D. Jay
Celano, Emma C.
Voloschin, Alfredo D.
Read, William L.
Olson, Jeffrey J.
License valid from 2016-08-09